Table 2.

Correlation between tetranectin expression and clinicopathological characteristics in patients with gastric cancer.

Clinicopathological Characteristics	No.	Tetranectinlow	%	Tetranectinhigh	%	P -value
	328
Gender						0.596
Male	215	147	68	68	32
Female	113	74	65	39	35
Age						0.024
< 60	158	116	73	42	27
≧60	170	105	62	65	38
Tumor location						0.739
Cardiac	40	25	63	15	38
Body	82	57	70	25	30
Pylorus	206	139	67	67	33
Tumor differentiation						0.703
Well	13	10	77	3	23
Moderate	51	33	65	18	35
Poor	264	178	67	86	33
Lauren classification						0.266
Diffused Type	137	95	69	42	31
Intestinal Type	180	121	67	59	33
Mixed Type	11	5	45	6	55
T						0.013
T1	71	58	82	13	18
T2	30	21	70	9	30
T3	84	57	68	27	32
T4	143	85	59	58	41
N						0.005
N0	103	77	75	26	25
N1	55	41	75	14	25
N2	64	44	69	20	31
N3	106	59	56	47	44
M						0.137
M0	318	217	68	102	32
M1	10	4	40	5	50
TNM stages						0.003
I	73	61	84	12	16
II	76	52	68	24	32
III	170	104	61	66	39
IV	9	4	44	5	56